1h Free Analyst Time
The alzheimer's disease therapeutics market is forecasted to grow by USD 5.41 billion during 2023-2028, accelerating at a CAGR of 10.03% during the forecast period. The report on the alzheimer's disease therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by availability, research, and development of novel biomarkers, increasing awareness of Alzheimers disease, and strong pipeline coupled with approval of therapeutics.
The alzheimer's disease therapeutics market is segmented as below:
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- E-commerce pharmacy
By Drug Class
- Cholinesterase inhibitors
- N-methyl-D-aspartate receptor antagonist
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the alzheimer's disease therapeutics market covers the following areas:
- Alzheimer's disease therapeutics market sizing
- Alzheimer's disease therapeutics market forecast
- Alzheimer's disease therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Drug Class
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The analyst recognizes the following companies as the key players in the global alzheimer's disease therapeutics market: AB Science SA, AbbVie Inc., AgeneBio Inc., Biogen Inc., Cipla Ltd., Curasia Medilab, Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Grifols SA, H Lundbeck AS, Johnson and Johnson, Lifecare Neuro Products Ltd., Lupin Ltd., Novartis AG, Pfizer Inc., Psycogen Captab, Solco Healthcare, Teva Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is emergence of regenerative therapies.'
According to the report, one of the major drivers for this market is the availability, research, and development of novel biomarkers.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AB Science SA
- AbbVie Inc.
- AgeneBio Inc.
- Biogen Inc.
- Cipla Ltd.
- Curasia Medilab
- Denali Therapeutics Inc.
- Eisai Co. Ltd.
- Eli Lilly and Co.
- Grifols SA
- H Lundbeck AS
- Johnson and Johnson
- Lifecare Neuro Products Ltd.
- Lupin Ltd.
- Novartis AG
- Pfizer Inc.
- Psycogen Captab
- Solco Healthcare
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
